Pfizer, Inc.

Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 73.92, indicating elevated leverage, while an interest coverage ratio of 4.22 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged posted a return on equity (ROE) of 4.98, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.13, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.18M in revenue per employee across its workforce of 76,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged recorded an income tax benefit of -232.75M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 5.97B, leaving 6.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 11.09, while the 200-day moving average is 10.54.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 16.17B, while operating income came in at 24.15B.

As of June 30, 2026, Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged holds 16.60B in cash and equivalents against 89.69B in total debt, resulting in a net debt position of 88.30B. Total book value stands at 120.90B, with working capital of 12.36B providing operational flexibility.

Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged produced 19.02B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs Unsponsored Canadian Depository Receipt Hedged posted a gross margin of 73.18, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 6.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 221.98 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.